[Skip to Content]
[Skip to Content Landing]
Views 256
Citations 0
Invited Commentary
April 23, 2018

Suggestions for Improving Conflict of Interest Processes in the US Food and Drug Administration Advisory Committees—Past Imperfect

Author Affiliations
  • 1Center for Science in the Public Interest, Washington, DC
JAMA Intern Med. Published online April 23, 2018. doi:10.1001/jamainternmed.2018.1324

The effect of financial conflicts of interest on voting behavior in US Food and Drug Administration (FDA) Advisory Committee meetings is frequently discussed, with research generally identifying small effects.1-3 This limited body of research justifies the FDA’s current approach to such conflicts. Members with conflicts of interest meeting the FDA’s criteria are excluded from meetings, unless “the need for the individual’s services outweighs the potential for a conflict of interest created by the financial interest involved.”4 In such cases, a waiver is issued, permitting participation in that meeting.

First Page Preview View Large
First page PDF preview
First page PDF preview
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Limit 140 characters
Limit 3600 characters or approximately 600 words